section name header

Evidence summaries

Melatonin for Cognitive Impairment

Melatonin is probably not effective in managing the cognitive sequelae of dementia. However, it may have effect on psychopathologic behavior. Level of evidence: "C"

A Cochrane review [Abstract] 1 included 5 studies with a total of 334 patients with dementia. Approximately 85% of the patients had a diagnosis of Alzheimer disease. The primary goal of 4 studies was to measure the effects of melatonin on sleep disorders as compared with placebo. Secondary outcomes included changes in cognitive and non-cognitive function, depressive and neuropsychiatric symptoms, and functions in activities of daily living. There were non-significant effects revealed from the pooled estimates from 3 trials (n=268, treatment time 4-7 weeks) of MMSE cognitive, and ADAS-cognitive change scores (WMD 0.29, 95% CI -0.63 to 1.22). Individual study estimates demonstrated a significant improvement for melatonin in behavioural and affective symptoms as measured by the ADAS non-cognitive scale in a study of 20 patients and in the Neuropsychiatric Inventory (NPI) (WMD -3.48, 95% CI -4.89 to -2.07), but not with 10 mg/day (IR) melatonin in a larger study of 157 patients (WMD 0.63, 95% CI -4.58 to 5.84). The remainder of the treatment effects for affect, behaviour and activities of daily living were non-significant.

Comment: The quality of evidence is downgraded by indirectness (differences in studied patients and outcomes) and by imprecise results (limited study size for each comparison).

    References

    • Jansen SL, Forbes DA, Duncan V, Morgan DG. Melatonin for cognitive impairment. Cochrane Database Syst Rev 2006;(1):CD003802 [Last assessed as up-to-date: 8 December 2009]. [PubMed]

Primary/Secondary Keywords